Full access
Legal News
Published Online: 18 June 2010

Illegal Drug Promotion Costs Company Half-Billion Dollars

Jun YanAuthors Info & Affiliations
Publication: Psychiatric News
Volume 45, Number 12
https://doi.org/10.1176/pn.45.12.psychnews_45_12_025
Track CitationsAdd to favorites

Abstract

The settlement of a federal lawsuit resolves yet another of the massive lawsuits drug companies have faced in recent years over off-label promotions of psychiatric drugs.
AstraZeneca has agreed to pay $520 million to settle a federal civil lawsuit in which the company was accused of illegally promoting its antipsychotic drug quetiapine, marketed under the brand name Seroquel, for unapproved indications.
The April 27 announcement marked the latest case in a string of federal lawsuits filed by the Department of Justice (DoJ) against major drug companies involving off-label drug marketing.
Last fall, Pfizer paid a record $2.3 billion to settle cases involving illegal promotions of four drugs, including ziprasidone (Geodon) and pregabalin (Lyrica) (Psychiatric News, October 2, 2009). Previous cases involving off-label promotions included ones against Eli Lilly for marketing olanzapine (Zyprexa), BristolMyers Squibb for marketing aripiprazole (Abilify), and Cephalon for marketing modafinil (Provigil).
Federal prosecutors alleged that from 2001 through 2006 AstraZeneca promoted quetiapine for treating unapproved conditions, including aggression, agitation, dementia, attention-deficit/hyperactivity disorder, depression, posttraumatic stress disorder, and insomnia.
Last December, the FDA approved quetiapine as an adjunctive treatment for depression but rejected the company's application for its use in depression as a monotherapy.
The lawsuit alleged that the company targeted off-label promotion to primary care physicians, pediatricians, and geriatricians “who do not typically treat schizophrenia or bipolar disorders,” according to the DoJ statement. The company was also accused of influencing continuing medical education programs it sponsored to promote the off-label use of quetiapine.
Quetiapine is one of AstraZeneca's leading products and accounted for more than $4.8 billion in worldwide sales in 2009. However, AstraZeneca recently announced that as part of a corporate restructuring, it plans to eliminate its research and development programs involving medications to treat psychiatric disorders.
In the settlement of the federal suit, AstraZeneca denied any wrongdoing. The company continues to face more than 10,000 civil suits filed by individuals alleging personal injuries, primarily development of diabetes, due to taking quetiapine.

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 45 • Number 12 • June 18, 2010
Pages: 13

History

Published online: 18 June 2010
Published in print: June 18, 2010

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.